Lyrica pregabalin regulatory update

The American Academy of Neurology (AAN) issued a new guideline recommending Pfizer's Lyrica pregabalin to treat diabetic neuropathic pain. The guidelines stated that the GABA receptor agonist is established as effective in lessening pain and also improves quality of life. Lyrica is approved in Europe to treat neuropathic pain, epilepsy and generalized anxiety disorder (GAD) and in the U.S. to treat fibromyalgia, neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, and as adjunctive therapy for adults with partial onset seizures. Pfizer co-promotes Lyrica in Japan with Eisai Co. Ltd. (Tokyo:4523; Osaka:4523, Tokyo, Japan). ...